These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1824638)

  • 1. Cost-effectiveness of hepatitis B screening in a mental health institution.
    Leonard J; Holtgrave DR; Johnson RP
    J Fam Pract; 1991 Jan; 32(1):45-8. PubMed ID: 1824638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
    Kim SY; Billah K; Lieu TA; Weinstein MC
    Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
    Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
    Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit analysis of hepatitis B vaccination.
    Jönsson B
    Postgrad Med J; 1987; 63 Suppl 2():27-32. PubMed ID: 3120169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen.
    Schalm SW; Mazel JA; de Gast GC; Heijtink RA; Botman MJ; Bänffer JR; Cerards LJ; Zwijnenberg J; Fetter WP; Nuijten SM
    Pediatrics; 1989 Jun; 83(6):1041-8. PubMed ID: 2726331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Berger S; Shouval D
    Bull World Health Organ; 1992; 70(6):757-67. PubMed ID: 1486673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of screening for only anti-HBc in institutions for mentally retarded persons.
    Akhter MN; Van Tiunen M; Metzger R; Goins J
    Am J Ment Retard; 1987 Nov; 92(3):279-81. PubMed ID: 3122797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necessity for routine obstetric screening for hepatitis B surface antigen.
    Greenspoon JS; Martin J; Greenspoon RL; McNamara BT
    J Reprod Med; 1989 Sep; 34(9):655-8. PubMed ID: 2530344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of different alternatives of universal vaccination against hepatitis B in the region of Murcia].
    Guillén Grima F; Espín Ríos MI
    Med Clin (Barc); 1995 Feb; 104(4):130-6. PubMed ID: 7898156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela].
    Fernández Barboza R; Rivero D; Echeverría B; Machado IV
    Bol Oficina Sanit Panam; 1991 Jul; 111(1):16-23. PubMed ID: 1834080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates.
    Jacobs RJ; Rosenthal P; Meyerhoff AS
    Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.
    Mulley AG; Silverstein MD; Dienstag JL
    N Engl J Med; 1982 Sep; 307(11):644-52. PubMed ID: 6810170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of prevaccination screening for hepatitis B antibody.
    Jacobson JJ; La Turno DE; Johnston FK; Shipman C
    J Dent Educ; 1987 Feb; 51(2):94-7. PubMed ID: 3100594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A cost-effectiveness analysis of vaccination against the hepatitis B virus].
    Antoñanzas F; Forcén T; Garuz R
    Med Clin (Barc); 1992 Jun; 99(2):41-6. PubMed ID: 1630178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-benefit analysis of vaccinal prevention of hepatitis B policy].
    Kerleau M; Flori YA; Nalpas B; Lanoé JL; Berthelot P; Fardeau-Gautier M
    Rev Epidemiol Sante Publique; 1995; 43(1):48-60. PubMed ID: 7892516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.